+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetes Associated Ophthalmic Treatment Market - Global Forecast 2026-2032- Product Image
Diabetes Associated Ophthalmic Treatment Market - Global Forecast 2026-2032- Product Image
New

Diabetes Associated Ophthalmic Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716081
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Diabetes Associated Ophthalmic Treatment Market is evolving rapidly, reshaped by innovation in therapeutics, diagnostics, and care delivery models. Senior decision-makers in healthcare, pharmaceuticals, and medtech can leverage this report to navigate emerging pathways that enhance operational efficiency, patient outcomes, and competitive positioning.

Market Snapshot: Diabetes Associated Ophthalmic Treatment Market

In 2025, the global diabetes-associated ophthalmic treatment market was valued at USD 6.74 billion, with growth to USD 7.36 billion expected in 2026. Forecasts indicate continued expansion at a compound annual growth rate (CAGR) of 10.09%, reaching a projected market size of USD 13.23 billion by 2032.

Scope & Segmentation

  • Treatment Modalities: Pharmacologic therapies (anti-VEGF agents, corticosteroids), device-based interventions, laser therapies, and minimally invasive surgical options.
  • Route of Administration: Intravitreal injection, systemic (oral or intravenous), topical ocular application, and surgical delivery.
  • Patient Subgroups: Type 1 Diabetes, Type 2 Diabetes; diverse progression patterns and comorbidities inform clinical strategies.
  • End-User Settings: Hospitals, ambulatory surgical centers, ophthalmology clinics, and retail pharmacies define access and delivery pathways.
  • Technology Platforms: Biologics, sustained-release implants, device-assisted administration, automated imaging, digital diagnostics, and telemedicine-enabled care.
  • Regional Coverage: Americas; Europe, Middle East & Africa (EMEA); Asia-Pacific, each with unique regulatory, economic, and care delivery landscapes.

Key Takeaways

  • Biologic innovation supports longer-lasting, multi-targeted treatments, prompting shifts in frequency, capacity planning, and safety monitoring across ophthalmic practices.
  • Delivery advances, including device-assisted tools and alternative administration routes, streamline workflows and broaden therapeutic options, especially for complex cases or suboptimal responders.
  • Early diagnosis and individualized planning are enabled by AI-driven image analysis and telemedicine, facilitating patient triage and streamlined access to specialty care.
  • Supply chain resilience and adaptive procurement strategies mitigate risks from external shocks and regulatory changes while ensuring consistent therapy delivery to key clinical sites.
  • Regional differences in reimbursement, healthcare infrastructure, and technology adoption drive the need for localized commercialization and operational planning.
  • Close collaboration between pharma, device makers, and diagnostic partners accelerates integrated solutions, supporting comprehensive screening-to-treatment care models.

Tariff Impact & Supply Chain Response

Recent tariff reforms have shifted procurement priorities and increased landed costs for critical drug inputs and ophthalmic devices. Companies have adopted nearshoring and diversified sourcing, restructured manufacturing footprints, and modified logistics to limit exposure to tariff volatility. These changes have led to closer alignment between clinical teams and supply chain professionals in choosing therapies that balance efficacy and cost while strengthening continuity strategies against episodic policy disruptions. Regulatory navigation and flexible packaging formats further contribute to supply chain sustainability.

Methodology & Data Sources

The research draws on comprehensive clinical literature reviews, interviews with ophthalmology experts, supply chain leaders, and operational stakeholders in real-world care settings. Data were triangulated with regulatory filings, peer-reviewed studies, and practitioner input to ensure accuracy on both clinical and market dynamics. Scenario analysis provided further assessment of the impact of recent trade and regulatory changes.

Why This Report Matters

  • Supports evidence-based strategy design by connecting clinical advances with operational imperatives and regional requirements.
  • Enables product and portfolio managers to align development, commercialization, and procurement initiatives with evolving standards of care in diabetic eye disease treatment.
  • Helps market access, regulatory, and reimbursement teams prepare for the impact of supply shifts and region-specific adoption challenges.

Conclusion

This report offers actionable insights at the intersection of innovation, care delivery, and commercial execution in diabetes-associated ophthalmic care. Stakeholders can anticipate, adapt, and respond to evolving market and regulatory demands for sustainable growth and patient-focused outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type
8.1. Anti-VEGF
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Brolucizumab
8.1.4. Faricimab
8.1.5. Ranibizumab
8.2. Corticosteroids
8.2.1. Dexamethasone Implant
8.2.2. Fluocinolone Implant
8.2.3. Triamcinolone
8.3. Laser Therapy
8.3.1. Focal/Grid Photocoagulation
8.3.2. Panretinal Photocoagulation
8.4. Surgical Intervention
9. Diabetes Associated Ophthalmic Treatment Market, by Route Of Administration
9.1. Intravitreal Injection
9.1.1. Prefilled Syringe
9.1.2. Vial
9.2. Systemic
9.2.1. Intravenous
9.2.2. Oral
9.3. Topical
9.3.1. Eye Drops
9.3.2. Ointments
10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type
10.1. Type 1 Diabetes
10.2. Type 2 Diabetes
11. Diabetes Associated Ophthalmic Treatment Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Hospitals
11.3. Ophthalmology Clinics
11.4. Retail Pharmacies
12. Diabetes Associated Ophthalmic Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Diabetes Associated Ophthalmic Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Diabetes Associated Ophthalmic Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Diabetes Associated Ophthalmic Treatment Market
16. China Diabetes Associated Ophthalmic Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Adverum Biotechnologies, Inc.
17.6. Aerpio Therapeutics, Inc.
17.7. Alimera Sciences, Inc.
17.8. Apexian Pharmaceuticals, Inc.
17.9. Bayer AG
17.10. Boehringer Ingelheim International GmbH
17.11. F. Hoffmann-La Roche Ltd
17.12. Genentech, Inc.
17.13. Glycadia Pharmaceuticals, Inc.
17.14. Kodiak Sciences Inc.
17.15. Kubota Vision, Inc.
17.16. MingSight Pharmaceuticals, Inc.
17.17. Novartis AG
17.18. Ocular Therapeutix, Inc.
17.19. Oxurion NV
17.20. Regeneron Pharmaceuticals, Inc.
17.21. Regenxbio Inc.
17.22. RemeGen Co., Ltd.
17.23. Santen Pharmaceutical Co., Ltd.
List of Figures
FIGURE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 147. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 152. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 153. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 169. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 171. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 173. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 174. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 175. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 176. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 192. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 193. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 194. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 196. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 197. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 198. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 203. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 204. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 205. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 207. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 208. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 209. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 210. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 224. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 225. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 226. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 227. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 229. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 230. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 231. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 232. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 235. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 236. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 237. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 238. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 240. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 241. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 242. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 246. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 247. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 248. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 249. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 251. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 252. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 253. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 254. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 269. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
TABLE 270. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 271. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
TABLE 272. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 274. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
TABLE 275. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 276.

Companies Mentioned

The key companies profiled in this Diabetes Associated Ophthalmic Treatment market report include:
  • Adverum Biotechnologies, Inc.
  • Aerpio Therapeutics, Inc.
  • Alimera Sciences, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann‑La Roche Ltd
  • Genentech, Inc.
  • Glycadia Pharmaceuticals, Inc.
  • Kodiak Sciences Inc.
  • Kubota Vision, Inc.
  • MingSight Pharmaceuticals, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Oxurion NV
  • Regeneron Pharmaceuticals, Inc.
  • Regenxbio Inc.
  • RemeGen Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.23 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report - Product Image

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Diabetes Injection Pens Market - Global Forecast 2026-2032 - Product Image

Diabetes Injection Pens Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Needle Free Diabetes Care Market - Global Forecast 2026-2032 - Product Image

Needle Free Diabetes Care Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Inadequately Controlled Type-II Diabetes Treatment Market Report 2025 - Product Image

Inadequately Controlled Type-II Diabetes Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Diabetes Management Supplements Market Outlook, 2030 - Product Image

Diabetes Management Supplements Market Outlook, 2030

  • Report
  • 187 Pages
  • Global
From

About the Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment market encompasses a range of medical procedures, devices, and medications utilized in the management and care of eye conditions associated with diabetes, specifically diabetic retinopathy and diabetic macular edema. Diabetic retinopathy involves changes to retinal blood vessels that can cause them to bleed or leak fluid, distorting vision. Treatments for these conditions range from laser surgery to control bleeding to the administration of anti-VEGF drugs, which help to reduce abnormal blood vessel growth and swelling. Intravitreal injections of steroids can also be utilized for their anti-inflammatory effects. Additionally, there is a growing interest in the development and use of novel drug delivery systems and surgical instruments to improve the precision and efficacy of treatments. Furthermore, technological advancements in optical coherence tomography (OCT) aids in the early detection and management of diabetic eye diseases by providing high-resolution images of the retina. Regular screening among diabetic patients is crucial for early intervention and has become an integral part of diabetes care, helping to prevent vision loss. Several companies have established positions in the market, which include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Abbott. These companies are involved in the production of therapeutics like anti-VEGF injections, as well as manufacturing devices and supplies for laser treatments and surgeries tailored to mitigate the ocular complications that arise from diabetes. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.